VTYX — Ventyx Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $314.81m
- $62.59m
- 31
- 28
- 13
- 13
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.18 | 7.05 | 67.1 | 113 | 208 |
Operating Profit | -4.18 | -7.05 | -67.1 | -113 | -208 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.33 | -28.2 | -83.7 | -108 | -193 |
Net Income After Taxes | -4.33 | -28.2 | -83.7 | -108 | -193 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.33 | -28.2 | -83.7 | -108 | -193 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.33 | -28.2 | -85.3 | -108 | -193 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.088 | -0.576 | -1.69 | -2.07 | -3.29 |
Dividends per Share |